Valeria Gaudieri1, Carmela Nappi2, Wanda Acampa1,2, Emilia Zampella2, Roberta Assante2, Teresa Mannarino2, Andrea Genova2, Giovanni De Simini2, Michele Klain2, Guido Germano3,4, Mario Petretta5, Alberto Cuocolo6. 1. Institute of Biostructure and Bioimaging, National Council of Research, Naples, Italy. 2. Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy. 3. Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 4. David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. 5. Department of Translational Medical Sciences, University Federico II, Via Pansini 5, 80131, Naples, Italy. 6. Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy. cuocolo@unina.it.
Abstract
BACKGROUND: Left ventricular (LV) remodeling is associated with adverse cardiovascular events. We evaluated the added prognostic value of LV shape index (SI) assessed by gated single-photon emission tomography (SPECT) in patients without known coronary artery disease (CAD). METHODS AND RESULTS: We studied 674 patients with normal myocardial perfusion and normal LV ejection fraction (EF) on stress gated SPECT imaging. An automated software program was used to calculate end-diastolic and end-systolic LVSI. An LVSI ≤ 0.54 at end-systole was considered normal. Follow-up was 96% complete with a median follow-up of 37 months. During follow-up, 25 events occurred (3.8% cumulative event rate). Event-free survival was lower in patients with abnormal end-systolic LVSI (P < .001). Age (P = .021), diabetes (P = .048), and end-systolic LVSI (P < .001) were independent predictors of events. LVSI added prognostic information increasing the global chi-square of the model including age and diabetes from 15.15 to 25.97 (P < .001). The effect of diabetes on hazard ratio increased with increasing values of end-systolic LVSI. The probability of events at 48 months predicted by Weibull analysis progressively increased with increasing values of end-systolic LVSI and was higher in patients with diabetes as compared to those without. Decision curve analyses indicate that the model including end-systolic LVSI resulted in an increased net benefit between 5% and 30% threshold probability, indicating superior estimation of outcomes at low threshold probability levels. CONCLUSIONS: The evaluation of LVSI may identify patients with early-stage LV remodeling and at higher risk of adverse cardiac events, even in the presence of normal myocardial perfusion.
BACKGROUND: Left ventricular (LV) remodeling is associated with adverse cardiovascular events. We evaluated the added prognostic value of LV shape index (SI) assessed by gated single-photon emission tomography (SPECT) in patients without known coronary artery disease (CAD). METHODS AND RESULTS: We studied 674 patients with normal myocardial perfusion and normal LV ejection fraction (EF) on stress gated SPECT imaging. An automated software program was used to calculate end-diastolic and end-systolic LVSI. An LVSI ≤ 0.54 at end-systole was considered normal. Follow-up was 96% complete with a median follow-up of 37 months. During follow-up, 25 events occurred (3.8% cumulative event rate). Event-free survival was lower in patients with abnormal end-systolic LVSI (P < .001). Age (P = .021), diabetes (P = .048), and end-systolic LVSI (P < .001) were independent predictors of events. LVSI added prognostic information increasing the global chi-square of the model including age and diabetes from 15.15 to 25.97 (P < .001). The effect of diabetes on hazard ratio increased with increasing values of end-systolic LVSI. The probability of events at 48 months predicted by Weibull analysis progressively increased with increasing values of end-systolic LVSI and was higher in patients with diabetes as compared to those without. Decision curve analyses indicate that the model including end-systolic LVSI resulted in an increased net benefit between 5% and 30% threshold probability, indicating superior estimation of outcomes at low threshold probability levels. CONCLUSIONS: The evaluation of LVSI may identify patients with early-stage LV remodeling and at higher risk of adverse cardiac events, even in the presence of normal myocardial perfusion.
Authors: Aiden Abidov; Piotr J Slomka; Hidetaka Nishina; Sean W Hayes; Xingping Kang; Shunichi Yoda; Ling-De Yang; James Gerlach; Fatma Aboul-Enein; Ishac Cohen; John D Friedman; Paul B Kavanagh; Guido Germano; Daniel S Berman Journal: J Nucl Cardiol Date: 2006-09 Impact factor: 5.952
Authors: Wanda Acampa; Mario Petretta; Laura Evangelista; Stefania Daniele; Evgjeni Xhoxhi; Maria Luisa De Rimini; Corrado Cittanti; Filippo Marranzano; Marco Spadafora; Sergio Baldari; Luigi Mansi; Alberto Cuocolo Journal: Eur J Nucl Med Mol Imaging Date: 2011-11-23 Impact factor: 9.236
Authors: T Sharir; G Germano; P B Kavanagh; S Lai; I Cohen; H C Lewin; J D Friedman; M J Zellweger; D S Berman Journal: Circulation Date: 1999-09-07 Impact factor: 29.690
Authors: G Germano; P B Kavanagh; P Waechter; J Areeda; S Van Kriekinge; T Sharir; H C Lewin; D S Berman Journal: J Nucl Med Date: 2000-04 Impact factor: 10.057
Authors: David A Bluemke; Richard A Kronmal; João A C Lima; Kiang Liu; Jean Olson; Gregory L Burke; Aaron R Folsom Journal: J Am Coll Cardiol Date: 2008-12-16 Impact factor: 24.094